A Phase II Study of Perifosine Plus Imatinib Mesylate for Patients With Resistant Gastrointestinal Stromal Tumor.
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Perifosine (Primary) ; Imatinib
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 04 Mar 2013 Trial company changed from AOI Pharmaceuticals to AEterna Zentaris as reported by ClinicalTrials.gov.
- 16 Oct 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History